Incidence of herpes zoster and its complications in Germany, 2005–2009

Hillebrand, Kathrin; Bricout, Hélène; Schulze‐Rath, Renate; Schink, Tania; Garbe, Edeltraut

doi:10.1016/j.jinf.2014.08.018

Cited by 90 publications

(98 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The HZ incidence in persons with immunosuppression was around twice as high as in immunocompetent persons (12 vs. 6/1,000 PY; [29]). …”

Section: Epidemiologymentioning

confidence: 95%

“…A total of approx. 28% of HZ cases led to one or more complications [29]. The risk of complicated disease progression increased with age, and was slightly higher among persons with immunosuppression than among immunocompetent persons with HZ.…”

Section: Epidemiologymentioning

confidence: 97%

Section: Epidemiologymentioning

confidence: 99%

“…The incidence is higher among women than among men, and rises continuously from around the age of 50 years [28][29][30]. Based on statutory health insurance (SHI) data, the age-specific incidence of HZ ranges from 4 cases per 1,000 person-years (PY) among persons under the age of 50 to 14 cases per 1,000 PY among 80-89-year-olds [29]. Claims data from the associations of statutory health insurance physicians reveal similar findings, with the incidence of HZ at 6.2/1,000 PY among 50-54-year-olds rising to 13.2/1,000 PY among those 90 years of age and older [28].…”

Section: Epidemiologymentioning

confidence: 99%

See 3 more Smart Citations

Background paper to the decision not to recommend a standard vaccination with the live attenuated herpes zoster vaccine for the elderly in Germany

2017

Bundesgesundheitsbl

View full text Add to dashboard Cite

“…The HZ incidence in persons with immunosuppression was around twice as high as in immunocompetent persons (12 vs. 6/1,000 PY; [29]). …”

Section: Epidemiologymentioning

confidence: 95%

Section: Epidemiologymentioning

confidence: 97%

Section: Epidemiologymentioning

confidence: 99%

Section: Epidemiologymentioning

confidence: 99%

See 2 more Smart Citations

Background paper to the decision not to recommend a standard vaccination with the live attenuated herpes zoster vaccine for the elderly in Germany

2017

Bundesgesundheitsbl

View full text Add to dashboard Cite

“…In the United Kingdom, one study reported that the median age at HZ diagnosis was 62 years (interquartile range 48-73) [13]. The IR was more or less stable between the ages of 10 and 44 years (at around 2.4 per thousand personyears), but increased more than threefold, to reach 15 in the 80-84 year old age group [12]. In the same study population, the IR was 36 % higher in females than in males [12].…”

mentioning

confidence: 99%

Herpes zoster vaccine: a shot to maintain wellbeing

Michel¹

2015

Aging Clin Exp Res

View full text Add to dashboard Cite

The current era is full of contradictory vaccine issues. The emerging Ebola pandemic stimulates the world's citizens who are calling for the urgent development of vaccine to prevent the disease [1]. They seem to be suddenly remembering that vaccines represent a major advancement in public health [2]. While the complete eradication of polio, neonatal tetanus, congenital rubella, and measles are still the main targets in less developed countries [3], inhabitants of high-resource countries are focusing on rare adverse effects of vaccines to discredit the efficacy and effectiveness of vaccination. As a result, there is an increase in vaccine-preventable diseases in both children and adults. Indeed, it has been estimated that ten times more adults (40 to 50 thousand) die than children in the USA annually from potentially vaccine-preventable diseases [4].In this controversial context, alongside vaccines for lifethreatening diseases, there have emerged new vaccines to prevent the occurrence of diseases and their complications. Herpes zoster (HZ) vaccine [5][6][7], is the best example of such quality improvement vaccines. In this issue, Stefania Maggi and collaborators present a comprehensive and upto-date review of how the HZ vaccine improves healthy ageing [8]. This paper raises some questions concerning the global epidemiology of the disease, improved knowledge of HZ risk factors, the well-known and more surprising consequences of the disease, as well as the increasing dilemma about age and the new indications for the currently available vaccine.The incidence rate (IR) of HZ in Italy, at 6.3 per thousand person-years [8,9], is higher than the mean incidence rate of 3-5 per thousand person-years reported in an analysis of 130 studies conducted in 26 countries in North America, Europe, and Asia-Pacific [10]. This could be related to a temporal increase in the incidence of HZ, often occurring before the introduction of varicella vaccination programmes [11], as in Finland [11] and Germany [12]. In the United Kingdom, one study reported that the median age at HZ diagnosis was 62 years (interquartile range 48-73) [13]. The IR was more or less stable between the ages of 10 and 44 years (at around 2.4 per thousand personyears), but increased more than threefold, to reach 15 in the 80-84 year old age group [12]. In the same study population, the IR was 36 % higher in females than in males [12]. Prodromic pain was experienced by 69.5 % of South Korean patients, of whom 95.1 % had moderate-to-severe pain [14]. In Italy, postherpetic neuralgia (PHN) occurred in 20.6 and 9.2 % of HZ patients older than 50 years after 3 and 6 months respectively [8,15], which corresponds to the mean 6-month PHN risk reported in the world literature [16].The risk factors for HZ have recently been better identified, and Maggi's paper describes them in detail [8]. However, it is important to insist on a few of these factors. In a study cohort of 144,959 adults diagnosed with herpes zoster between 2000 and 2011, severely immunosuppressive conditions r...

show abstract

Herpes Zoster and Risk of Incident Parkinson's Disease in US Veterans: A Matched Cohort Study

Tunnicliffe,

Weil,

Breuer

et al. 2024

Movement Disorders

View full text Add to dashboard Cite

BackgroundAlthough some systemic infections are associated with Parkinson's disease (PD), the relationship between herpes zoster (HZ) and PD is unclear.ObjectiveThe objective is to investigate whether HZ is associated with incident PD risk in a matched cohort study using data from the US Department of Veterans Affairs.MethodsWe compared the risk of PD between individuals with incident HZ matched to up to five individuals without a history of HZ using Cox proportional hazards regression. In sensitivity analyses, we excluded early outcomes.ResultsAmong 198,099 individuals with HZ and 976,660 matched individuals without HZ (median age 67.0 years (interquartile range [IQR 61.4–75.7]); 94% male; median follow‐up 4.2 years [IQR 1.9–6.6]), HZ was not associated with an increased risk of incident PD overall (adjusted HR 0.95, 95% CI 0.90–1.01) or in any sensitivity analyses.ConclusionWe found no evidence that HZ was associated with increased risk of incident PD in this cohort. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

show abstract

Incidence of herpes zoster and its complications in Germany, 2005–2009

Cited by 90 publications

References 35 publications

Background paper to the decision not to recommend a standard vaccination with the live attenuated herpes zoster vaccine for the elderly in Germany

Background paper to the decision not to recommend a standard vaccination with the live attenuated herpes zoster vaccine for the elderly in Germany

Herpes zoster vaccine: a shot to maintain wellbeing

Herpes Zoster and Risk of Incident Parkinson's Disease in US Veterans: A Matched Cohort Study

Contact Info

Product

Resources

About